Abstracts tagged "analgesics"

Abstract Number: 2049 • 2019 ACR/ARP Annual Meeting
National Estimates of Pain Medication Use in Patients with Osteoarthritis
Mohammed Saeed¹, ¹Capital Health, Trenton, NJ
Background/Purpose: The epidemiology of pain medication use among patients with osteoarthritis is not well explored. Chronic kidney disease (CKD) modifies choice of analgesics. The aim…
Abstract Number: 2195 • 2019 ACR/ARP Annual Meeting
BMI Has Minimal Effect on Reduction of Symptoms in Patients with Osteoarthritis of the Knee Treated with Diclofenac 1% Gel
Joel A. Block¹, Bharat Patel ² and Sandy Yacoub Garas ³, ¹Rush University Medical Center, Chicago, IL, ²GlaxoSmithKline Consumer Healthcare, Weybridge, United Kingdom, ³GlaxoSmithKline Consumer Healthcare, Warren, NJ
Background/Purpose: Clinical trials demonstrate that diclofenac sodium gel 1% (DSG 1%), a topical NSAID, provides significantly better pain relief than vehicle placebo for patients with…
Abstract Number: 2197 • 2019 ACR/ARP Annual Meeting
Clinically Relevant Improvements in Knee Osteoarthritis Pain with Diclofenac Sodium Gel 1%
Marc C. Hochberg¹, Bharat Patel ², Sandy Yacoub Garas ³ and Roy Altman ⁴, ¹University of Maryland School of Medicine, Baltimore, MD, ²GlaxoSmithKline Consumer Healthcare, Weybridge, United Kingdom, ³GlaxoSmithKline Consumer Healthcare, Warren, NJ, ⁴University of California, Los Angeles
Background/Purpose: Topical agents are recommended for the initial treatment of patients with knee osteoarthritis (OA). Diclofenac sodium gel 1% (DSG 1%), a topical nonsteroidal anti-inflammatory…
Abstract Number: 425 • 2018 ACR/ARHP Annual Meeting
Efficacy, Safety, and Tolerability of ONO-4474, an Orally Available Pan-Tropomyosin Receptor Kinase Inhibitor, in Japanese Patients with Moderate-to-Severe Osteoarthritis of the Knee: A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Study
Naoki Ishiguro¹, Shusuke Oyama², Ryunosuke Higashi³ and Kunio Yanagida⁴, ¹Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Data Science, Ono Pharmaceutical Co., Ltd., Osaka, Japan, ³Translational Science, Translational Medicine Center, Ono Pharmaceutical Co., Ltd., Osaka, Japan, ⁴Translational Science, Translational Medicine Center, Ono Pharmaceutical Co., Ltd, Osaka, Japan
Background/Purpose: ONO-4474 is an orally available, peripheral-specific, pan-tropomyosin receptor kinase (pan-Trk) inhibitor currently under development for treatment of musculoskeletal pain in OA patients. This study…
Abstract Number: 1374 • 2018 ACR/ARHP Annual Meeting
The Relationship between Loneliness and Osteoarthritis in US Adults from a Nationally Representative Survey
Adeela Cheema¹, Louise Hawkley², Kristen Wroblewski³ and Kichul Ko⁴, ¹Section of Geriatrics and Palliative Medicine, Department of Medicine, University of Chicago, Chicago, IL, ²NORC, University of Chicago, Chicago, IL, ³Department of Public Health Sciences, University of Chicago, Chicago, IL, ⁴Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL
Background/Purpose: Loneliness in adults is a growing phenomenon across the Western world. It is associated with increased mortality, depression, coronary heart disease and stroke. Moreover,…
Abstract Number: 15L • 2017 ACR/ARHP Annual Meeting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients with Osteoarthritis of the Hip or Knee
Sukirti Bagal, Catherine Munera, Patricia Brady and Joseph Stauffer, Cara Therapeutics, Stamford, CT

Background/Purpose: CR845 is a selective kappa opioid receptor agonist with a peripheral mechanism of action. Here we report preliminary results from a Phase 2b study…
Abstract Number: 389 • 2017 ACR/ARHP Annual Meeting
S-110483 a New Potent EP4 Receptor Antagonist with Immunomodulatory and Analgesic Activities
Takashi Maeda¹, Toshitaka Ochiai², Toshie Nagayasu-Tanaka¹, Yuta Morisaki¹, Haruka Takizawa¹, Seiji Ishihara¹, Shigeo Kurokawa¹, Kiyoharu Ukai¹ and Masahiro Suda¹, ¹Pharmacology Department, Kaken Pharmaceutical Co., LTD, Kyoto, Japan, ²Kaken Pharmaceutical Co., LTD, Kyoto, Japan
Background/Purpose: Prostaglandin (PG) E2 is known to enhance the expansion of T helper 17 (Th17) cell population via EP4 receptor (EP4) in the early phase…
Abstract Number: 374 • 2016 ACR/ARHP Annual Meeting
Anxiolytic Effects of the Novel α2δ Ligand Mirogabalin (DS-5565) in Sluka Model, an Experimental Animal Model of Fibromyalgia
Yuki Domon¹, Naohisa Arakawa¹, Hiroyasu Murasawa², Hiroyuki Kobayashi², Kensuke Saeki² and Yutaka Kitano¹, ¹Pain & Neuroscience Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan, ²Nihon Bioresearch Inc., Hashima, Japan
Anxiolytic Effects of the Novel Alpha-2-Delta Ligand Mirogabalin (DS-5565) in Sluka Model, an Experimental Animal Model of Fibromyalgia Yuki Domona, Naohisa Arakawaa, Hiroyasu Murasawab, Hiroyuki…
Abstract Number: 2186 • 2016 ACR/ARHP Annual Meeting
Analgesic Use and Subsequent Risk of Falls in Participants with or at Risk of Knee Osteoarthritis
Wei-Hsuan Lo-Ciganic¹, Lysbeth Floden², Erin L. Ashbeck³, Lili Zhou¹ and C. Kent Kwoh^3,4, ¹Department of Pharmacy, Practice and Science, University of Arizona, College of Pharmacy, Tucson, AZ, ²Department Pharmacy, Practice and Science, University of Arizona, College of Pharmacy, Tucson, AZ, ³The University of Arizona Arthritis Center, Tucson, AZ, ⁴Rheumatology, University of Arizona, College of Medicine, Tucson, AZ
Background/Purpose: Analgesics including opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants, and nutraceuticals are commonly used for pain relief in osteoarthritis (OA). Although it has been reported…
Abstract Number: 2224 • 2016 ACR/ARHP Annual Meeting
Influence of Caffeine on Opioid Analgesics in Fibromyalgia
J. Ryan Scott¹, Daniel J. Clauw², Chad M. Brummett¹, Richard E. Harris¹, Afton L. Hassett¹ and Steven E. Harte³, ¹Anesthesiology, University of Michigan, Ann Arbor, MI, ²Chronic Pain & Fatigue Research Center, University of Michigan, Ann Arbor, MI, ³Department of Anesthesiology, University of Michigan, Ann Arbor, MI
Background/Purpose: Caffeine’s action as an NSAID adjuvant are well understood, yet little clinical research has explored its effects on opioid analgesia. We present data from…
Abstract Number: 1427 • 2015 ACR/ARHP Annual Meeting
Analgesic Effects of the Novel Alpha-2-Delta Ligand Mirogabalin (DS-5565) in Experimental Animal Models of Fibromyalgia
Yuki Domon¹, Naohisa Arakawa¹, Shun-ichi Yasuda², Kensuke Saeki², Mayumi Kano², Masami Kato² and Yutaka Kitano¹, ¹Biological Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan, ²Hashima Laboratory, Nihon Bioresearch Inc., Gifu, Japan
Background/Purpose: Mirogabalin (DS-5565) is a novel ligand of the α2δ subunit of voltage-gated calcium channels. Mirogabalin possesses unique binding characteristics to α2δ subunits, and potent…
Abstract Number: 1437 • 2015 ACR/ARHP Annual Meeting
Prevalence of Pain, Its Impact and Management in a Population-Based Cohort of Patients with Rheumatoid Arthritis: Data from the Australian Rheumatology Association Database
Bethan Richards^1,2, Rachelle Buchbinder³, Marissa N. Lassere⁴ and Lyn March⁵, ¹Sydney Medical School, University of Sydney, Sydney, Australia, ²Royal Prince Alfred Hospital, Mulgrave, Vic, Australia, ³Monash Department of Clinical Epidemiology, Cabrini Institute and Monash University, Melbourne, Australia, ⁴Dept of Rheumatology, St George Hospital, Kogarah, Australia, ⁵Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia
Background/Purpose: Despite advances in the treatments available for rheumatoid arthritis (RA), many patients continue to experience musculoskeletal pain. Untreated and under-treated pain are well known to increase…
Abstract Number: 2232 • 2015 ACR/ARHP Annual Meeting
Risk of Osteoporotic Fractures with Use of Cyclooxygenase-2 Inhibitors
Deepan Dalal¹, Devyani Misra², Christine Peloquin³, Tuhina Neogi⁴, Yuqing Zhang⁵, David T. Felson⁶ and Maureen Dubreuil⁷, ¹Rheumatology, Boston Medical Center, Boston, MA, ²Medicine, Section of, BUSM, Boston, MA, ³Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁴Clinical Epidemiology, BUSM, Boston, MA, ⁵BUSM, Boston, MA, ⁶Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁷Rheumatology, Boston VA HealthCare System, Boston, MA
Background/Purpose: In animal models, cyclo-oxygenase (COX)-2 stimulates osteoclasts through prostaglandin E2 (PGE2). Therefore, non-steroidal anti-inflammatory drugs (NSAIDs) preferentially inhibiting COX-2 (ie-coxibs) should prevent bone…
Abstract Number: 2241 • 2014 ACR/ARHP Annual Meeting
Intermittent Analgesic Use and Risk of Pain Exacerbation in Knee Osteoarthritis: A Web Based Case-Crossover Study
Tahereh Erfani¹, Yuqing Zhang², Joanna Makovey¹, Ben Metcalf³, Lyn March¹, Kim Bennell³ and David J. Hunter¹, ¹Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ²Boston University School of Medicine, Boston, MA, ³University of Melbourne, Melbourne, Australia
Background/Purpose: The pain experienced by osteoarthritis (OA) patients is neither constant nor stable and most patients experience episodes of pain exacerbations or flares. A number…
Abstract Number: 1451 • 2014 ACR/ARHP Annual Meeting
Use of Analgesics in Patients with Knee and/or Hip Osteoarthritis: Results from the Amsterdam Osteoarthritis Cohort
Joyce van Tunen¹, Marike van der Leeden^1,2, Martin van der Esch¹, Leo D. Roorda¹, Willem F. Lems^3,4 and Joost Dekker⁵, ¹Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ²Rehabilitation Medicine/EMGO, VU University Medical Center, Amsterdam, Netherlands, ³Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose Use of analgesics is recommended by international guidelines to reduce pain complaints related to knee and/or hip osteoarthritis. Underuse of analgesics might be substantial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].